Making Light Work of Blood Clotting
Posted by SR in News, tags: cardiovascular, drug targeting
The ability to selectively switch enzymes on and off in a particular tissue could offer many improved treatment options, and scientists at the University of Florida have now devised a way of achieving this goal. Writing in the journal PNAS, they describe a molecule consisting of a DNA aptamer attached by a polyethylene glycol linker to a complementary strand of DNA with azobenzene molecules attached. The aptamer was chosen to bind selectively to the enzyme thrombin and block its role in blood coagulation. In visible light, the azobenzene double bonds are in the trans-conformation and the aptamer is prevented from binding to thrombin by hybridisation with the complementary strand of DNA. When irradiated with ultraviolet light, however, the azobenzene molecules flip into the cis-conformation causing dissociation of the duplex and unveiling the aptamer which can then bind to thrombin and inhibit blood clotting.
The team hope that the technique could one day be used to cut off the blood supply to solid tumours or to produce controlled release versions of drugs which would be activated only in the target tissue, thus reducing the risk of side effects. Endoscopic lights could be used to activate the drugs or, in some cases, it may be sufficient to irradiate skin close to the target site with near-infrared light which penetrates the skin.
Related posts:
- New Blood Pressure Target Although normally clinically silent, persistent hypertension and atherosclerosis are leading risk factors for strokes, heart attacks, heart failure, aneurysms and...
- Thrombin Receptor Antagonist Meets Primary Endpoints Results of a phase II clinical trial of a novel oral thrombin receptor antagonist (TRA) were published in the March...
- Renin Links CMV Infection to High Blood Pressure Human cytomegalovirus (hCMV) is a widespread member of the herpes family of viruses, with well over half of the world’s...
- Engineering New Cancer Treatments Metastasis, the spread of cancer cells to new organs, generally signals a poor prognosis but detecting circulating tumour cells is...
- Chymase Inhibitors Could Improve Outcomes for Heart Failure Patients Angiotensin converting enzyme (ACE) inhibitors are widely used for the treatment of hypertension and heart failure. The beneficial effects of...
Related posts brought to you by Yet Another Related Posts Plugin.
This entry was posted on Wednesday, April 15th, 2009 at 8:38 am and is filed under News. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Entries (RSS)